DiaMedica Therapeutics price target raised to $11 from $7 at Lake Street

Lake Street raised the firm’s price target on DiaMedica Therapeutics (DMAC) to $11 from $7 and keeps a Buy rating on the shares. The year could see three data readouts across both preeclampsia and stroke, with each a potential value-driver for shares, says the analyst, who calls the stock “a best idea in our universe for 2025.”